Sage Therapeutics (SAGE) Scheduled to Post Earnings on Thursday

Sage Therapeutics (NASDAQ:SAGE) will be issuing its quarterly earnings data before the market opens on Thursday, April 25th. Analysts expect the company to announce earnings of ($1.58) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.28) by $0.73. The firm had revenue of $77.97 million for the quarter, compared to the consensus estimate of $60.15 million. Sage Therapeutics had a negative return on equity of 54.41% and a negative net margin of 626.32%. The firm’s quarterly revenue was up 2621.5% compared to the same quarter last year. During the same quarter last year, the business posted ($2.47) EPS. On average, analysts expect Sage Therapeutics to post $-6 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Sage Therapeutics Stock Down 19.6 %

NASDAQ:SAGE opened at $12.57 on Thursday. The company has a market capitalization of $755.58 million, a PE ratio of -1.39 and a beta of 0.86. The stock’s 50 day moving average price is $20.06 and its 200 day moving average price is $20.96. Sage Therapeutics has a 52-week low of $10.92 and a 52-week high of $59.99.

Analyst Ratings Changes

A number of analysts have commented on the company. Wedbush reiterated a “neutral” rating and set a $24.00 target price on shares of Sage Therapeutics in a research report on Wednesday. StockNews.com upgraded Sage Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, February 15th. Royal Bank of Canada upped their target price on Sage Therapeutics from $21.00 to $26.00 and gave the company a “sector perform” rating in a research note on Thursday, February 15th. Bank of America lowered Sage Therapeutics from a “neutral” rating to an “underperform” rating and dropped their price target for the stock from $24.00 to $14.00 in a research note on Wednesday. Finally, Morgan Stanley increased their target price on Sage Therapeutics from $20.00 to $22.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 28th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $40.56.

Hedge Funds Weigh In On Sage Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SAGE. KBC Group NV bought a new stake in shares of Sage Therapeutics in the 4th quarter valued at about $28,000. MetLife Investment Management LLC bought a new position in shares of Sage Therapeutics during the first quarter worth approximately $34,000. Tower Research Capital LLC TRC increased its holdings in shares of Sage Therapeutics by 74.0% during the third quarter. Tower Research Capital LLC TRC now owns 5,050 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 2,148 shares during the period. XTX Topco Ltd bought a new position in shares of Sage Therapeutics during the first quarter worth approximately $209,000. Finally, Oracle Alpha Inc. acquired a new stake in shares of Sage Therapeutics during the 4th quarter worth approximately $222,000. 99.22% of the stock is owned by institutional investors and hedge funds.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.